60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.82M
Last updated: Nov 17, 2026 at 11:05 AM ET
60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) Earnings: Report Dates and Results
In the quarter ended Jun 30, 2026, 60 Degrees Pharmaceuticals, Inc. Common Stock reported EPS of -$0.90, below the -$0.74 estimate. It beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SXTP's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
Earnings History
Of the 11 quarters below that had an estimate, SXTP beat 3 and missed 8. Revenue for the quarter ended Jun 30, 2026 was $207898, down 32.5% from $307871 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.90 | -$0.74 | N/A | -21.62% | Miss | N/A | 1 | 0 up, 1 down | Aug 14, 2026 | $207898 |
| Mar 31, 2026 | -$1.21 | -$0.99 | -$0.99 - -$0.99 | -22.65% | Miss | N/A | 1 | 1 up, 0 down | May 15, 2026 | $162092 |
| Dec 31, 2025 | -$8.17 | -$8.00 | -$8.00 - -$8.00 | -2.12% | Miss | N/A | 1 | 0 up, 1 down | Mar 26, 2026 | $409110 |
| Sep 30, 2025 | -$2.53 | -$1.84 | -$1.84 - -$1.84 | -37.50% | Miss | N/A | 1 | 1 up, 0 down | Nov 13, 2025 | $528562 |
| Jun 30, 2025 | -$4.33 | -$4.96 | -$4.96 - -$4.96 | +12.70% | Beat | N/A | 1 | 1 up, 0 down | Aug 13, 2025 | $307871 |
| Mar 31, 2025 | -$1.56 | -$1.31 | N/A | -19.08% | Miss | N/A | 1 | 1 up, 0 down | May 15, 2025 | $256283 |
| Dec 31, 2024 | -$2.16 | -$0.18 | N/A | N/A | N/A | N/A | 1 | 1 up, 0 down | Mar 27, 2025 | $302588 |
| Sep 30, 2024 | -$17.35 | -$17.40 | -$18.60 - -$16.20 | +0.29% | Beat | -109.4% | 2 | 1 up, 0 down | Nov 14, 2024 | $148111 |
| Jun 30, 2024 | -$84.60 | -$33.60 | -$46.94 - -$20.17 | -151.79% | Miss | N/A | 2 | 1 up, 0 down | Aug 14, 2024 | $124972 |
| Mar 31, 2024 | -$31.54 | -$52.80 | N/A | +40.27% | Beat | N/A | 2 | 0 up, 0 down | Apr 1, 2024 | $105674 |
| Dec 31, 2023 | -$0.35 | -$0.14 | -$0.27 - -$0.14 | -146.43% | Miss | N/A | 2 | 0 up, 0 down | Feb 28, 2024 | $118273 |
| Sep 30, 2023 | $184.80 | $228.00 | -$62.42 - $518.61 | -18.95% | Miss | N/A | 2 | 0 up, 0 down | Nov 20, 2023 | $51188 |
| Jun 30, 2023 | -$1.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 25, 2023 | $62648 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$16.59, after -$135.65 the year before. It was $183.36 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$16.59 | N/A |
| Dec 31, 2024 | -$135.65 | -174.0% |
| Dec 31, 2023 | $183.36 | N/A |
Frequently Asked Questions About SXTP
Did SXTP beat earnings estimates last quarter?
No. 60 Degrees Pharmaceuticals, Inc. Common Stock reported EPS of -$0.90 for the quarter ended Jun 30, 2026, below the -$0.74 estimate by 21.62%.
What EPS do analysts expect from SXTP next quarter?
The consensus EPS estimate for 60 Degrees Pharmaceuticals, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$0.80 from 4 analysts, with estimates from -$0.87 to -$0.70.
How often does SXTP beat earnings estimates?
60 Degrees Pharmaceuticals, Inc. Common Stock beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate, with an average surprise of -30.22%.
SXTP pages: Overview, Earnings, Forecast, Financials, Competitors